To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of the availability of Creon to treat Type 2 diabetes.

The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used by patients with conditions such as type 2 diabetes, cystic fibrosis, and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.

We have issued comprehensive guidance to healthcare professionals about these supply issues, which provide advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.

We understand how distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and help mitigate risks to patients.